Med spa consolidation, valuation multiples and buyer activity, with what it means for owners who want to protect what they've built.
Med spa M&A is active and institutional, yet still early. More than 50 aesthetics transactions were announced in each of 2023 and 2024, and 42 in 2025. More than 90% of U.S. med spas remain independently owned. Sponsor-backed platforms accounted for six of the ten most recent transactions we tracked. Published multiples range from about 3x EBITDA for small practices to 12x for scaled regional platforms. The spread between those numbers is the story. It is driven less by size than by one question: does the EBITDA belong to the business, or to the founder?
Large enough to support institutional platforms.
A deep acquisition universe.
Consolidation runway remains long.
Most operators are below institutional scale.
Recurring demand supports revenue visibility.
A meaningful consumer-healthcare wallet.
Consolidation in medical aesthetics is no longer new. It is not finished, either.
The sector is institutional enough to support repeat acquirers, dedicated corporate development teams and sponsor-backed platforms. It is fragmented enough that those same buyers can still build regional density one add-on at a time.
Volume eased in 2025. Buyers did not leave. They became more selective, spending longer on quality of earnings, provider retention and whether acquired EBITDA will actually transfer.
The ten transactions below are ordered newest first. Purchase prices were generally not disclosed. Many announcements use the word "partnership," so we preserve that language where control economics were not made public. Details are drawn from public press releases and company announcements.
Olympus's first Tennessee practice, combining surgery and nonsurgical aesthetics. The platform now operates in nine states.
Annapolis flagship plus two Spa by Sullivan locations, integrating surgery, med spa and skincare.
Two operating Dallas-area clinics plus development rights for a third site.
A Denver med spa and the buyer's first U.S. clinic acquisition.
An established Austin med spa sold to new owner-operators.
Denver and Encinitas locations. Alpha now reports 36 locations across 12 states.
Four practices plus a provider-education platform.
A three-market expansion in a single announcement.
Two Denver-area locations. The platform also secured $120M in committed growth financing.
A Waco physician-led practice joining a national aesthetics platform.
The press release says partnership. Read closely. Some of these are control transactions and some are not. For an owner, the word on the announcement matters far less than who controls the practice after close, and how you get paid.
Tony Siebel, Founder and Managing Director, Olympic M&A
One more pattern is worth noting. Buyers are broadening beyond injectables into surgery, skincare, wellness and longevity. The end state looks less like a single-service med spa and more like a broader consumer-healthcare platform.
The buyer universe is deeper than the announced deal list suggests. Several platforms now employ dedicated M&A, corporate development or partnership executives. Sourcing deals has become an institutional capability, not an occasional event.
That matters for sellers in two ways. It supports liquidity for well-run practices. It also means the buyer across the table has done this many times before. Most owners will do it once.
| Platform | Backer or ownership | Model |
|---|---|---|
| Olympus Cosmetic Group | VSS | Multi-state surgery and nonsurgical aesthetics platform; recent entry into Tennessee. |
| Empower Aesthetics | Shore Capital | National platform built through physician-led add-ons. |
| Alpha Aesthetics Partners | Thurston Group | Partnership model pairing med spas with provider education. |
| Princeton Medspa Partners | Princeton Equity Group | Buy-and-build platform with $120M in committed growth capital. |
| AYA Medical Spa | Eagle Merchant Partners | Scaled platform entering premium urban markets by acquisition. |
| Inspire Aesthetics | Hidden Harbor | Surgery plus aesthetics; med spa revenue extends patient relationships. |
| Advanced MedAesthetic Partners | Leon Capital Group | Partnership platform offering centralized growth resources. |
| SkinSpirit | KKR (minority) | Large multi-location operator with institutional backing. |
| Cosmetic Physician Partners | Practitioner-owned | Physician-owned MSO; an alternative to PE-backed consolidation. |
| Vos Collection | Persistence Capital Partners | Institutional capital building a broader portfolio of clinics. |
| MD Esthetics | New Harbor Capital | Sponsor-backed medical aesthetics platform. |
| Aesthetic Partners | Norwest Venture Partners | Sponsor-backed medical aesthetics platform. |
| Elase Med Spas | Imperial Capital | Sponsor-backed medical aesthetics platform. |
| Skin & Aesthetic Centers | Abacus Investments | Sponsor-backed medical aesthetics platform. |
| Premier Plastic Surgery Partners | Corbel Capital Partners | Plastic surgery platform with aesthetics services. |
Florida, Texas and California remain the clearest cluster of platform and MSO activity, combining population growth, consumer demand and large independent-practice universes.
The more recent pattern is expansion beyond those three states. Olympus entered Tennessee. Cosmetic Physician Partners added Maryland. Alpha built density in Colorado, California and Massachusetts while adding provider-training capability.
The next phase looks less like a national land grab and more like regional density around strong local brands. Secondary metros are the likely next wave.
Two med spas with the same revenue can trade at very different multiples. These are the factors that explain the gap.
| Factor | Premium profile | Average profile | Discounted profile |
|---|---|---|---|
| Provider concentration | Several productive clinicians; no single provider drives economics | One or two providers matter, with coverage | Founder or one injector drives most revenue |
| Recurring demand | High rebooking, documented cohorts, membership and skincare attachment | Repeat business visible but not measured | Promotion-led or episodic |
| Management | Central admin and SOPs; founder can step back | Strong manager, founder still involved | Founder runs scheduling, marketing and recruiting |
| Growth quality | Same-store growth and provider productivity | Growth with some paid-acquisition dependence | Growth depends on new sites or discounting |
| Financial quality | Clean monthly reporting, defensible add-backs | Usable reporting, needs normalization | Weak books or aggressive add-backs |
| Provider alignment | Retention mechanisms and a succession bench | Key staff likely to stay, little formal alignment | Key injectors can leave at close |
| Equipment | Well-utilized devices with proven demand | Some device concentration | Heavy leases, underused equipment |
| Compliance | Clean ownership, delegation and sourcing | No known issue; diligence remains | Structural issues that may delay closing |
Related: Key factors private equity firms consider in medical aesthetics acquisitions
There is no single med spa multiple. There is a ladder.
Each step up reflects less owner dependence, more management depth and more predictable revenue. Size tends to follow those qualities. It does not replace them.
A simple example shows why the ladder matters. A practice with $1.5M in adjusted EBITDA valued at 5x is worth $7.5M. The same earnings at 7x are worth $10.5M.
Same earnings. Same patients. A $3M difference.
That gap is usually closed by preparation, not negotiation alone.
Buyers are not paying for how busy you are today. They are paying for how much of today's EBITDA will still be there after you step back. That single question explains most of the distance between a 4x outcome and an 8x outcome.
Tony Siebel, Founder and Managing Director, Olympic M&A
The headline multiple is only half the offer.
2025 med spa transactions ranged from roughly 60% cash and 40% rollover to 80% cash and 20% rollover, sometimes with earnouts or holdbacks layered on top. Two offers that both say "7x" can deliver very different outcomes.
When comparing offers, look past the multiple:
Two offers can both say seven times. One puts most of the value in your hands at closing. The other asks you to bet a large share on someone else's execution. Compare the structure, not the headline.
Tony Siebel, Founder and Managing Director, Olympic M&A
Aesthetics combines healthcare delivery with repeat consumer spending. Neurotoxins need maintenance. Fillers are repeated. Lasers are sold in series. Skincare is replenished. Memberships bring patients back.
The 2026 operating data add an important nuance. Growth is coming from existing patients, not new ones.
Members spend two and a half times what non-members spend.
Recurring relationships materially improve revenue visibility.
Fast lead response and online booking correlated with stronger growth.
Same-store productivity, rebooking, memberships and provider utilization transfer to a new owner. A growth story built only on new locations or paid acquisition does not transfer as well.
Related: The evolution of consolidation in medical aesthetics
Transaction volume should remain healthy. The highest multiples will concentrate in practices with durable same-store growth, provider depth, recurring revenue and centralized infrastructure.
A funded buyer set is already in place. Expect add-ons around existing markets more than a wave of new national entrants.
Longer diligence. Closer monitoring through closing. More pressure on unstable providers and aggressive add-backs.
Recurring patient economics will increasingly appear in buyer underwriting.
Clusters share recruiting, management and local brand awareness.
Successful recaps would recycle capital into the sector and increase competition for quality add-ons.
Lower rates help. The case still rests on cash-pay revenue, fragmentation and transferable earnings.
If one provider leaves or cuts hours, the acquired earnings can leave too.
Corporate practice of medicine, delegation and scope rules vary by state.
FDA enforcement and DSCSA requirements make vendor authorization and lot tracing an investment-level issue.
Underused equipment becomes stranded fixed cost.
Practices that rely on promotions or financing face more pressure in a softer economy.
Centralization can erode provider autonomy, local brand equity and patient relationships if handled poorly.
You don't have to sell tomorrow. But you should know how buyers think today.
A few questions worth asking yourself, quietly:
The highest-value sale processes are prepared before a buyer arrives. A seller should be able to show that earnings are real, repeatable and transferable, rather than asking the buyer to reconstruct the business during diligence.
Preparation directly impacts outcome.
When you're ready, we're here for a confidential conversation about your practice, what buyers are paying today and how to protect what you've built. No pressure. No prep needed. Explore at your own pace.
Olympic M&A has advised on $100M+ in completed healthcare transactions. Named among the Top 50 Healthcare M&A Advisors, 2025. Senior advisors lead every engagement — no handoffs, no junior teams.
Most med spas are valued as a multiple of adjusted EBITDA. Published 2025–2026 ranges run from roughly 3x–6x for smaller practices under $4M in revenue to 7x–12x for scaled regional platforms. Where a practice lands depends mostly on whether its earnings transfer to a new owner or stay tied to the founder.
There is no single med spa multiple. Recent published ranges are about 3x–6x for small med spas, 5x–8x for mid-sized practices with $4M–$20M in revenue, and 7x–12x for large regional platforms. Multi-provider practices with recurring revenue and $1M–$3M in EBITDA have been benchmarked at 7x–9x.
More than 90% of U.S. med spas remain independently owned, revenue is largely cash-pay and recurring, and smaller practices trade below scaled platforms. That combination supports a buy-and-build strategy: acquire founder-led practices, keep the providers and local brand, centralize non-clinical work and build regional density.
Buyers reward recurring revenue from neurotoxins, memberships and treatment series; low dependence on any single provider; clean adjusted EBITDA; strong patient retention; a credible local brand; and a clean clinical and legal structure covering ownership, delegation, medical direction and drug sourcing.
Start 12–24 months ahead. Clean up monthly financial reporting and document add-backs, spread production across more than one provider, build membership and rebooking programs, retire underused device leases, and review ownership, supervision and drug-sourcing documentation before a buyer does.
Rollover equity is the portion of the purchase price a seller reinvests in the buyer's platform instead of taking in cash. 2025 med spa deals commonly ranged from about 60% cash and 40% rollover to 80% cash and 20% rollover. Rollover can create a second payout later, but its value depends on the platform's performance.
This content is for informational and educational purposes only and does not constitute financial, legal, or investment advice. Consult with your own advisors before making any decisions. Valuation estimates are based on general market data and may not reflect your specific situation. Actual results depend on numerous factors including financial performance, market conditions, and deal structure. Multiple ranges reflect published market observations, not guarantees. Past transactions do not guarantee future outcomes. Company names are referenced from public announcements; Olympic M&A did not advise on the transactions listed unless stated.